Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.

Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, Xu XX.

Mol Carcinog. 2007 Feb;46(2):130-43.

PMID:
17131304
2.

Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.

Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX.

Cancer. 2002 Oct 15;95(8):1802-15.

3.

Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.

Cardillo MR, Di Silverio F, Gentile V.

Anticancer Res. 2006 Mar-Apr;26(2A):973-82.

5.

Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.

Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS.

Gynecol Oncol. 1996 Jul;62(1):89-99.

PMID:
8690299
6.

Collagenase expression in ovarian cancer cell lines.

Moore DH, Allison B, Look KY, Sutton GP, Bigsby RM.

Gynecol Oncol. 1997 Apr;65(1):78-82.

PMID:
9103395
8.
9.

Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.

Ripley D, Tunuguntla R, Susi L, Chegini N.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1794-800.

PMID:
17009974
10.

Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.

Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC.

BMC Cancer. 2009 Jan 14;9:20. doi: 10.1186/1471-2407-9-20.

11.

Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.

Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX.

Cancer. 2003 Dec 15;98(12):2607-23.

12.

Expression and localization of mRNAs for matrix metalloproteinases and their inhibitors in mixed bronchioloalveolar carcinomas with invasive components.

Kanomata N, Nakahara R, Oda T, Aoyagi Y, Ishii G, Yokose T, Hasebe T, Nagai K, Yokozaki H, Ochiai A.

Mod Pathol. 2005 Jun;18(6):828-37.

13.
14.

Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.

Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Daraï E.

Int J Oncol. 2008 Dec;33(6):1239-46.

PMID:
19020757
15.

Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity.

Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP.

Anticancer Res. 2001 Nov-Dec;21(6A):3821-8.

PMID:
11911253
16.

Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma.

Bister V, Skoog T, Virolainen S, Kiviluoto T, Puolakkainen P, Saarialho-Kere U.

Mod Pathol. 2007 Nov;20(11):1128-40. Epub 2007 Sep 14.

17.

Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of intravasation and metastasis.

Partridge JJ, Madsen MA, Ardi VC, Papagiannakopoulos T, Kupriyanova TA, Quigley JP, Deryugina EI.

J Biol Chem. 2007 Dec 7;282(49):35964-77. Epub 2007 Sep 25.

18.

Metalloproteinase expression in normal and malignant oral keratinocytes: stimulation of MMP-2 and -9 by scatter factor.

Bennett JH, Morgan MJ, Whawell SA, Atkin P, Roblin P, Furness J, Speight PM.

Eur J Oral Sci. 2000 Aug;108(4):281-91.

PMID:
10946762
19.

[Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].

Demeter A, Szirmai K, Oláh J, Papp Z, Jeney A.

Orv Hetil. 2004 Aug 1;145(31):1617-24. Hungarian.

PMID:
15384859
20.

Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells.

Wu M, Xu G, Xi L, Wei J, Song A, Han Z, Zhou J, Wang S, Zhu T, Zhang A, Lu Y, Ma D.

Oncol Rep. 2006 Feb;15(2):501-5.

PMID:
16391876

Supplemental Content

Support Center